Printer Friendly

Bristol-Myers Squibb Company passes US FDA's approval for Evotaz tablets in combination with antiretroviral agents for HIV-1 infection in adults.

M2 EQUITYBITES-February 2, 2015-Bristol-Myers Squibb Company passes US FDA's approval for Evotaz tablets in combination with antiretroviral agents for HIV-1 infection in adults

(C)2015 M2 COMMUNICATIONS http://www.m2.com

Medicine company Bristol-Myers Squibb Company (NYSE:BMY) disclosed on Wednesday the receipt of the US Food and Drug Administration's (FDA) approval for Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

The company said Evotaz is coformulated to be one pill, once-daily, combining the protease inhibitor atazanavir, which is marketed as Reyataz (atazanavir 200 mg/300 mg) capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences.

According to the company, Evotaz is the first and only protease inhibitor pharmacoenhanced by cobicistat that is supported by comparative Phase III trial data. The randomized, double-blind clinical trial evaluated the efficacy and safety of Reyataz 300 mg with cobicistat 150 mg (the components of Evotaz)versus Reyataz 300 mg with ritonavir 100 mg (Reyataz/ritonavir) in combination with emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults.

Patients had a baseline estimated CrCL >70mL/min, a mean baseline plasma HIV-1 RNA of 4.8 log10 copies/mL, and a mean baseline CD4+ cell count of 352 cells/mm, revealed the company .

This approval delivers proven suppression (HIV-1 RNA

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 2, 2015
Words:230
Previous Article:SCA posts profit before tax of SEK10,888m in 2014.
Next Article:Recipharm reports increase in total number of shares and votes during January 2015.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters